Company to maximize world-class EU-GMP operations, potentially opening future revenue- generating opportunities June 20, 2022 VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”) or the (“Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, has submitted a request... Read more
Ryan Allway May 19th, 2022 Psychedelics, Top News PharmAla to supply SABI Mind’s Healing Centres, subject to Health Canada approval VANCOUVER, BC, May 19, 2022 /CNW/ – PharmAla Biotech (CSE: MDMA) is pleased to announce that it has signed an agreement with SABI Mind Inc. which will allow for its GMP... Read more
PharmAla Biotech adds David Purcell as Director of Sales
March 14, 2022
Purcell to Accelerate PharmAla’s GMP MDMA Manufacturing and Sales Business VANCOUVER, BC, March 14, 2022 /CNW/ – In order to better serve its clinical trial customers, PharmAla Biotech Holdings Inc. (CSE: MDMA) is pleased to announce the hiring of Mr. David Purcell as Director of Sales. As a seasoned... Read more
Ryan Allway November 4th, 2020 App, Exclusive, Psychedelics, Top Story Most pharmaceutical and biotech investors are familiar with long commercialization timelines, but there are a few ways to shortcut the process. For example, the Food and Drug Administration provides Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review designations... Read more
- 1
- 2
